Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Rhonda E. Ries, MA, Amanda R. Leonti, MS, Timothy Junius Triche, Jr., PhD, Robert B. Gerbing, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Jenny L. Smith, MSc, MD, Todd M Cooper, DO, Jason E. Farrar, MD, Aniruddha J. Deshpande, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 461.

https://doi.org/10.1182/blood-2019-125943

Published: 2019

Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 682.

https://doi.org/10.1182/blood-2019-124901

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Aishath S Naeem, PhD, Winnie I Nguy, Svitlana Tyekucheva, PhD, Stacey M. Fernandes, BS, Vanessa Rai, BS, Kevin Ebata, PhD, Eliana B. Gomez, PhD, Barb J. Brandhuber, PhD, Stephen M. Rothenberg, MD PhD, Jennifer R Brown, MD PhD

Blood (2019) 134 (Supplement_1): 478.

https://doi.org/10.1182/blood-2019-124362

Published: 2019

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 4307.

https://doi.org/10.1182/blood-2019-124213

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Magalie Joris, Delphine Lebon, MD, Amandine Charbonnier, MD, Pierre Morel, MD, Berengere Gruson, MD, Alexis Caulier, MD, Caroline Delette, MD, Marie-Noëlle Lacassagne, Nicolas Guillaume, Loïc Garçon, Jean-Pierre Marolleau, MD PhD

Blood (2019) 134 (Supplement_1): 4600.

https://doi.org/10.1182/blood-2019-131314

Published: 2019

Journal Articles

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Nathan H. Fowler, MD, Judith Trotman, MBChB, FRACP, FRCPA, Rebecca Auer, MRCP, FRPath, PhD, Christopher R. Flowers, MD MS, William F. Reed, MD, Elena Ivanova, PhD, Jane Huang, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 5252.

https://doi.org/10.1182/blood-2019-122628

Published: 2019

Journal Articles

Mesenchymal Stem Cells Improve the Structure and Function of the Graft-Versus-Host Disease Receptor Thymus: CCR9 Plays an Important Role in Its Homing Thymus

Xin Zhang, Ke Zhao, MD, Jiabao He, Andy Peng Xiang, PhD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 5599.

https://doi.org/10.1182/blood-2019-125307

Published: 2019

Journal Articles

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, William Reed, MD, Chris Tankersley, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5256.

https://doi.org/10.1182/blood-2019-122629

Published: 2019

Journal Articles

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Ashwini M Patil, MSc, Stefanie Kesper, Vishal Khairnar, PhD, Marco Luciani, Michael Möllmann, Ulrich Dührsen, Prof, MD PhD, Joachim R Göthert, PD, MD

Blood (2019) 134 (Supplement_1): 2537.

https://doi.org/10.1182/blood-2019-125331

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Blood (2019) 134 (Supplement_1): 755.

https://doi.org/10.1182/blood-2019-126305

Published: 2019

Journal Articles

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

Sara Morrow, BA, Dennis Dobrovolsky, PhD, Eric Wang, PhD, Radosław P. Nowak, PhD, Katherine Donovan, PhD, Tyler Faust, PhD, Guang Yang, PhD, Zhengnian Li, PhD, Eric Fischer, Steven P Treon, MD PhD FRCP, David M Weinstock, MD, Nathanael S. Gray, PhD

Blood (2018) 132 (Supplement 1): 263.

https://doi.org/10.1182/blood-2018-99-116895

Published: 2018

Journal Articles

Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma

Jiye Liu, PhD, Wenrong Zhou, PhD, Lijie Xing, MD, Liang Lin, PhD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 1917.

https://doi.org/10.1182/blood-2018-99-111962

Published: 2018

Journal Articles

More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

Chia Sharpe, Joanne Davis, PhD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Dale I Godfrey, PhD, Adam Uldrich, PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Rachel Koldej, PhD, David Ritchie, MBChB, PhD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2018-99-117618

Published: 2018

Journal Articles

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

John C. Reneau, MD, Steven R. Hwang, MD, Carlos A. Murga-Zamalloa, MD, Joseph J. Buggy, PhD, James W. Janc, PhD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2018-99-110554

Published: 2018

Journal Articles

The Effect of Btk Inhibitors on Haemostasis and Thrombosis

Gasim Dobie, PhD, Daniel Man-yuen Sze, PhD, Constantine Tam, MD PhD, Denise Jackson, BAppSc (MLS), FAIMS, PhD FFSc

Blood (2018) 132 (Supplement 1): 1126.

https://doi.org/10.1182/blood-2018-99-109803

Published: 2018

Journal Articles

Assessing Hematologist's Knowledge of the Use of Ibrutinib and Acalabrutinib in B-Cell Malignancies

Lauren Willis, PharmD, Melinda Tanzola, PhD, Richard R. Furman, MD

Blood (2018) 132 (Supplement 1): 5861.

https://doi.org/10.1182/blood-2018-99-115343

Published: 2018

NARROW

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Mesenchymal Stem Cells Improve the Structure and Function of the Graft-Versus-Host Disease Receptor Thymus: CCR9 Plays an Important Role in Its Homing Thymus

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma

More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

The Effect of Btk Inhibitors on Haemostasis and Thrombosis

Assessing Hematologist's Knowledge of the Use of Ibrutinib and Acalabrutinib in B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only